Chemomab与Scipher合并后股权结构出炉:前者股东持股约32%,后者持股约68%

美股速递
Jul 08

根据双方达成的合并协议,在交易完成后,Chemomab Therapeutics Ltd.的现有股东预计将持有合并后新公司约32%的股权。与此同时,Scipher Medicine的现有股权持有人预计将获得新公司约68%的股份。这一股权分配方案明确了合并后实体的控制权结构。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10